文献

J-GLOBAL ID：202002233141509643   整理番号：20A2141230

Myc媒介SDHAアセチル化は遺伝子発現と腫瘍形成のエピジェネティックな調節を誘発する【JST・京大機械翻訳】

Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis

著者 (29件)： Li Shi-Ting (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Huang De (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Shen Shengqi (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Cai Yongping (Department of Pathology, School of Medicine, Anhui Medical University, Hefei, China) ,  Xing Songge (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Wu Gongwei (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Jiang Zetan (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Hao Yijie (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Yuan Mengqiu (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Yuan Mengqiu (Guangzhou First People’s Hospital, School of Medicine, Institutes for Life Sciences, South China University of Technology, Guangzhou, China) ,  Yuan Mengqiu (School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, China) ,  Wang Nana (Department of Pathology, School of Medicine, Anhui Medical University, Hefei, China) ,  Zhu Lianbang (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Yan Ronghui (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Yang Dongdong (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Wang Lin (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Liu Zhaoji (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Liu Zhaoji (Guangzhou First People’s Hospital, School of Medicine, Institutes for Life Sciences, South China University of Technology, Guangzhou, China) ,  Liu Zhaoji (School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, China) ,  Hu Xin (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Zhou Rongbin (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Qu Kun (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Li Ailing (Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China) ,  Duan Xiaotao (State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China) ,  Zhang Huafeng (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Gao Ping (Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China) ,  Gao Ping (Guangzhou First People’s Hospital, School of Medicine, Institutes for Life Sciences, South China University of Technology, Guangzhou, China) ,  Gao Ping (School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, China) ,  Gao Ping (Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China)
資料名： Nature Metabolism  (Nature Metabolism)
巻： 2  号： 3  ページ： 256-269  発行年： 2020年 
JST資料番号： W6371A  ISSN： 2522-5812  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 腫瘍形成におけるcMyc(またはMyc)の転写役割は,よく評価されている。しかし,遺伝子発現のエピジェネティックな調節に広範にMycがどのように関与するかは,完全には確立されていない。ここでは,アセチル化を介しコハク酸デヒドロゲナーゼ複合体サブユニットA(SDHA)を不活性化することにより,MycがH3K4me3活性化と遺伝子発現を生じる癌細胞で調節カスケードを誘導することを示す。MycはSIRT3デアセチラーゼのSKP2仲介分解の活性化によりSDHAのアセチル化依存性不活性化を促進することを見出した。さらに,SDH複合体活性のMyc阻害は,H3K4me3活性化および腫瘍特異的遺伝子発現を誘発する細胞コハク酸蓄積を誘導することを示した。Lys335でのアセチル化SDHAはin vitroおよびin vivoでの腫瘍増殖に寄与し,臨床試料における腫瘍形成の増加を確認した。この研究は,癌の進行に重要な,アセチル化に依存したSDHA不活性化と遺伝子発現のMyc駆動後成的調節の間の関係を示す。Liと同agueは,cMycがSIRT3のSKP2仲介分解の活性化によりコハク酸デヒドロゲナーゼ複合体サブユニットAアセチル化を促進することにより腫瘍形成を促進することを示す。これはコハク酸蓄積とその結果としての腫瘍特異的遺伝子発現をもたらす。Copyright The Author(s), under exclusive license to Springer Nature Limited 2020 Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： リチウム ,  *アセチル化 ,  コハク酸デヒドロゲナーゼ ,  *腫瘍 ,  腫瘍細胞 ,  サブユニット ,  複合体 ,  *遺伝子発現 ,  in vitro実験 ,  *腫瘤形成 ,  *エピジェネティクス ,  脂肪族カルボン酸 ,  ジカルボン酸
準シソーラス用語： 腫瘍成長 ,  デアセチラーゼ ,  *Myc蛋白質 , 【Automatic Indexing@JST】

分類 (2件)： 遺伝子発現  (EC02040Q) ,  生物学的機能  (EB03040U)

物質索引 (1件)： コハク酸

タイトルに関連する用語 (7件)： Myc ,  アセチル化 ,  遺伝子発現 ,  腫瘍形成 ,  エピジェネティック ,  調節 ,  誘発